PENDING CLAIMS

1. (**Original**) A method for identifying a test agent as reducing apoptosis of a macrophage cell comprising:

(a) providing:

(i) macrophage cells; and

(ii) a test agent; and

(b) contacting said macrophage cells in the presence of said test agent to produce contacted macrophage cells and in the absence of said test agent to produce control cells; and

(c) detecting reduced activity of Protein Kinase R in said treated cells compared to Protein Kinase R in said control cells, wherein said detecting identifies said test agent as reducing apoptosis of macrophage cells.

2. (**Canceled**).

3. (**Previously Presented**) The method of Claim 1 further comprising, d) identifying said test agent as anti-bacterial.

4. (**Canceled**).

5. (**Canceled**).

6. (**Original**) A method for reducing apoptosis of macrophage cells, comprising:

(a) providing:

(i) macrophage cells; and

(ii) an agent that reduces activity of Protein Kinase R; and

(b) contacting said macrophage cells with said agent under conditions such that said agent reduces activity of said Protein Kinase R.

7. (**Canceled**).

8. (**Original**) The method of Claim 6, wherein said macrophage cells are contacted with a molecule chosen from one or more of lipopolysaccharide, lipoteichoic acid, *Yersinia pseudotuberculosis* YopJ protein, and protein expressed by the *Salmonella typhimurium* SPI2 locus.

9. (**Original**) The method of Claim 6, wherein said macrophage cells are contacted with a bacterium.

10. (**Original**) The method of Claim 9, wherein said bacterium is gram-negative.

11. (**Original**) The method of Claim 10, wherein said gram-negative bacterium is one or more of *Yersinia species, Salmonella typhimurium*, and *H. influenza*.

12. (**Original**) The method of Claim 9, wherein said bacterium is gram-positive.

13. (**Original**) The method of Claim 12, wherein said gram-positive bacterium is a *B. anthracis*.

14. (**Original**) The method of Claim 6, wherein said macrophage cells are contacted with one or more of dsRNA and virus prior to contacting with a molecule chosen from one or more of lipopolysaccharide, lipoteichoic acid, *Yersinia pseudotuberculosis* YopJ protein, and protein expressed by the *Salmonella typhimurium* SPI2 locus.

15. (**Original**) The method of Claim 6, wherein said macrophage cells are contacted with one or more of dsRNA and virus prior to contacting with a bacterium.

16. (**Previously Presented**) The method of Claim 15, wherein said virus comprises *Influenza virus*.

17. (**Original**) A method of treating a microbial infection in a cell, comprising:

a) providing:

i) a cell with one or more symptoms of a microbial infection and

ii) a formulation comprising a Protein Kinase R inhibitor; and

b) administering said formulation to said cell under conditions such that said one or more symptoms of a microbial infection are reduced.

18. (**Original**) The method of Claim 17, wherein said cell has a microbial infection associated with one or more symptoms of a viral infection.

19. (**Original**) The method of Claim 17, wherein said microbe is a bacterium.

20. (**Previously Presented**) The method of Claim 19, wherein said bacterium is selected from the group consisting of *Bacillus species, Yersinia species, Salmonella species, Shigella species*, *Streptococcus species* and *Haemophilus species*.

21. (**Previously Presented**) The method of Claim 18, wherein said virus is selected from the group consisting of *Influenzavirus A, Influenzavirus B*, and *Influenzavirus C.*

22. (**Original**) The method of Claim 17, wherein said infection is a multiple infection.

23. (**Original**) The method of Claim 22, wherein said multiple infection comprises a bacteria infection and a virus infection.

24. (**Canceled**).

25. (**Previously Presented**) The method of Claim 17, wherein said cell is in a human patient.

26. (**Previously Presented**) The method of Claim 17, wherein said cell is in a nonhuman animal patient.

26. (**Canceled**).

27. (**Original**) A method of treating a microbial infection in a patient, comprising:

a) providing:

i) a patient with one or more symptoms of a microbial infection and

ii) a formulation comprising a Protein Kinase R inhibitor; and

b) administering said formulation to said patient under conditions such that said one or more symptoms of a microbial infection are reduced.

28. (**Original**) The method of Claim 27, wherein said patient has a microbial infection associated with one or more symptoms of a viral infection.

29. (**Original**) The method of Claim 18, wherein said infection is a bacterial infection.

30. (**Previously Presented**) The method of Claim 29, wherein said bacterium is selected from the group consisting of *Bacillus species, Yersinia species, Salmonella species, Shigella species*, *Streptococcus species* and *Haemophilus species*.

31. (**Previously Presented**) The method of Claim 28, wherein said virus is selected from the group consisting of *Influenzavirus A, Influenzavirus B*, and *Influenzavirus C*.

32. (**Original**) The method of Claim 27, wherein said infection is a multiple infection.

33. (**Original**) The method of Claim 32, wherein said multiple infection comprises a bacteria infection and a virus infection.

34. (**Canceled**).